Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459916 | 0.86 | NPC1 (0.54) | RAB9ANPC1KMT2AMEN1GRM7 | |
| SCHEMBL2458262 | 0.81 | RAB9A (0.57) | RAB9ANPC1KMT2AMEN1KDM4E | |
| SCHEMBL2458764 | 0.78 | HDAC1 (0.48) | RAB9ANPC1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2460515 | 0.76 | P2RX7 (0.62) | RAB9ANPC1KMT2AMEN1TSHR | |
| SCHEMBL2456219 | 0.75 | SMYD3 (0.61) | RAB9ANPC1KMT2A | |
| SCHEMBL2456714 | 0.75 | GPR183 (0.46) | RAB9A | |
| SCHEMBL28975690 | 0.74 | MEN1 (0.64) | RAB9ANPC1KMT2AMEN1CHRNA7 | |
| SCHEMBL2454974 | 0.73 | NPC1 (0.43) | RAB9ANPC1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2454980 | 0.73 | EGFR (0.42) | RAB9ANPC1LMNA | |
| SCHEMBL2460465 | 0.72 | SCN5A (0.40) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534277-B1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-09-14 | — | — | EP | disclosed |
| CN-100337626-C | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | AVENTIS PHARMA GMBH (DE) | 2007-09-19 | — | — | CN | disclosed |
| US-7105513-B2 | Cardiovascular disorders; strokes; hypotensive agents | SANOFI-AVERTIS DEUTSCHLAND GMBH (DE) | 2006-09-12 | — | — | US | disclosed |
| CN-1674895-A | Acylated, heteroaryl-fused cycloalkenylamines and their use as pharmaceuticals | AVENTIS PHARMA GMBH (DE) | 2005-09-28 | — | — | CN | disclosed |
| EP-1534277-A1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040092513-A1 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
| WO-2004014372-A1 | ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
| EP-1388342-A1 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2004-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092513-A1 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | LIPG, AADAC, AANAT | CA12 2911/4885CA1 4233/4885CA2 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.